Ken Griffin
CTKB icon

Ken Griffin’s Cytek Biosciences CTKB Stock Holding History

Ken Griffin’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.06M Buy
471,392
+304,638
+183% +$1.44M ﹤0.01% 6008
2025
Q4 		$842K Buy
166,754
+84,450
+103% +$392K ﹤0.01% 7794
2025
Q3 		$286K Sell
82,304
-534,781
-87% -$2.01M ﹤0.01% 10490
2025
Q2 		$2.1M Buy
617,085
+14,568
+2% +$48.5K ﹤0.01% 5621
2025
Q1 		$2.42M Buy
602,517
+401,377
+200% +$2.08M ﹤0.01% 5164
2024
Q4 		$1.31M Sell
201,140
-69,432
-26% -$414K ﹤0.01% 6497
2024
Q3 		$1.5M Buy
270,572
+213,444
+374% +$1.21M ﹤0.01% 6057
2024
Q2 		$319K Buy
+57,128
New +$343K ﹤0.01% 9017
2023
Q4 		– Sell
-404
Closed -$2.23K – 14377
2023
Q3 		$2.23K Sell
404
-755
-65% -$6.06K ﹤0.01% 13745
2023
Q2 		$9.9K Sell
1,159
-391,733
-100% -$3.51M ﹤0.01% 13233
2023
Q1 		$3.61M Buy
392,892
+343,750
+700% +$3.7M ﹤0.01% 4350
2022
Q4 		$502K Buy
+49,142
New +$660K ﹤0.01% 8225
2022
Q3 		– Sell
-264,928
Closed -$3.44M – 12753
2022
Q2 		$2.84M Buy
264,928
+239,579
+945% +$2.38M ﹤0.01% 4852
2022
Q1 		$273K Sell
25,349
-67,020
-73% -$905K ﹤0.01% 10795
2021
Q4 		$1.51M Buy
92,369
+77,051
+503% +$1.61M ﹤0.01% 6872
2021
Q3 		$328K Buy
+15,318
New +$360K ﹤0.01% 10871

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ken Griffin's CTKB Position: Q1 2026 in Review

Ken Griffin increased its Cytek Biosciences (CTKB) stake by 183% in Q1 2026, buying an estimated $1.44M and bringing the position to 471,392 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #6008.

Ken Griffin first reported a position in CTKB in Q3 2021 and has held it in 16 quarters since. The position peaked at $3.61M in Q1 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Ken Griffin held 471,392 shares of Cytek Biosciences worth $2.06M as of Q1 2026.
  • Ken Griffin bought 304,638 Cytek Biosciences shares in Q1 2026, an estimated $1.44M.
  • Cytek Biosciences made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6008 holding.
  • Ken Griffin first reported a position in Cytek Biosciences in Q3 2021 and has held it in 16 quarters since.
  • Ken Griffin's Cytek Biosciences position peaked at $3.61M in Q1 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.